These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8252498)

  • 61. Comment: clinical experiences of visual disturbances with nilutamide.
    Dijkman GA; Klotz LH; Diokno AC; Zippe CD
    Ann Pharmacother; 1997 Dec; 31(12):1550-2. PubMed ID: 9416403
    [No Abstract]   [Full Text] [Related]  

  • 62. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen.
    Berson A; Schmets L; Fisch C; Fau D; Wolf C; Fromenty B; Deschamps D; Pessayre D
    J Pharmacol Exp Ther; 1994 Jul; 270(1):167-76. PubMed ID: 8035313
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Fatal fulminating hepatitis caused by nilutamide. A new case].
    Marty F; Godart D; Doermann F; Mérillon H
    Gastroenterol Clin Biol; 1996; 20(8-9):710-1. PubMed ID: 8977826
    [No Abstract]   [Full Text] [Related]  

  • 64. [Drug treatment of prostatic carcinoma].
    Kool JC
    Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2202-3. PubMed ID: 9550808
    [No Abstract]   [Full Text] [Related]  

  • 65. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
    Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers].
    Jonville AP; Diot E; Dutertre JP; Autret E
    Therapie; 1992; 47(5):393-7. PubMed ID: 1299978
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fulminant hepatic failure due to nilutamide hepatotoxicity.
    Merwat SN; Kabbani W; Adler DG
    Dig Dis Sci; 2009 Apr; 54(4):910-3. PubMed ID: 18688719
    [No Abstract]   [Full Text] [Related]  

  • 68. Antiandrogens in the 21st century.
    Pisle ST; Figg WD
    Cancer Biol Ther; 2009 Sep; 8(17):1611. PubMed ID: 19823041
    [No Abstract]   [Full Text] [Related]  

  • 69. Consideration of chemical reaction mechanisms in relationship to the biological action of "dual antagonists".
    BARDOS TJ
    Biochem Pharmacol; 1962 Mar; 11():256-60. PubMed ID: 13864953
    [No Abstract]   [Full Text] [Related]  

  • 70. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.
    Ito Y; Sadar MD
    Res Rep Urol; 2018; 10():23-32. PubMed ID: 29497605
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacology of nilutamide.
    Gaillard-Moguilewsky M; de Gery A; Ulmann A
    Cancer; 1993 Dec; 72(12 Suppl):3828-9. PubMed ID: 8252498
    [No Abstract]   [Full Text] [Related]  

  • 72. Nilutamide approved for metastatic prostate cancer.
    Am J Health Syst Pharm; 1996 Dec; 53(23):2784. PubMed ID: 8957341
    [No Abstract]   [Full Text] [Related]  

  • 73. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
    Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
    Prostate; 1994; 24(1):17-23. PubMed ID: 8290386
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacology and clinical studies with RU 23908 (Anandron).
    Raynaud JP; Moguilewsky M; Tournemine C; Pottier J; Coussedière D; Salmon J; Husson JM; Bertagna C; Tremblay D; Pendyala L
    Prog Clin Biol Res; 1985; 185A():99-120. PubMed ID: 4034583
    [No Abstract]   [Full Text] [Related]  

  • 75. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.